Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial - Ensrud, K; LaCroix, A; Thompson, J R (Circulation, 2010)
, et al.